Sign In
Buy HZNP
$116.30
+0 (+0%)
At Close: Jan 04, 2024
3 Reasons Why Growth Investors Shouldn't Overlook Horizon Therapeutics (HZNP)
03:08pm, Tuesday, 19'th Oct 2021
Horizon Therapeutics (HZNP) possesses solid growth attributes, which could help it handily outperform the market.
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
09:58am, Wednesday, 13'th Oct 2021
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Horizon Therapeutics plc to Release Third-Quarter 2021 Financial Results and Host Webcast on Nov. 3, 2021
08:00am, Monday, 11'th Oct 2021
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its third-quarter 2021 financial results will be released on Wednesday, Nov. 3, 2021. Following the announcement,
Horizon Therapeutics plc Announces New Development Programs at Virtual R&D Day
07:00am, Wednesday, 29'th Sep 2021
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) will present an overview of its pipeline, including five new development programs for investigational medicines, daxdilimab (HZN-7734)
7 Biotech Stocks Entering the Golden Boom Phase
03:30pm, Tuesday, 28'th Sep 2021
These biotech stocks offer a more mature take on an otherwise risky sector. These companies already have successes under their belt.
4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace
09:10am, Thursday, 23'rd Sep 2021
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position REGN, MRNA, VRTX
HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline
07:30am, Tuesday, 21'st Sep 2021
CHARLOTTESVILLE, Va., Sept. 21, 2021 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potenti
Horizon Therapeutics reports record quarter
05:18pm, Wednesday, 15'th Sep 2021
Tim Walbert, Horizon Therapeutics Chairman and CEO, joins The Exchange to discuss his company's record run and the non-Covid pharmaceuticals the company is working on. For access to live and exclusive
3 Reasons Why Horizon Therapeutics (HZNP) Is a Great Growth Stock
02:31pm, Wednesday, 15'th Sep 2021
Horizon Therapeutics (HZNP) could produce exceptional returns because of its solid growth attributes.
Is Horizon (HZNP) a Great Growth Stock?
09:55am, Tuesday, 14'th Sep 2021
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Horizon (HZNP).
Horizon (HZNP) Begins Phase IV Study on Tepezza for Chronic TED
11:45am, Wednesday, 08'th Sep 2021
Horizon (HZNP) enrolls the first patient in a phase IV study evaluating the safety and efficacy of Tepezza for the treatment of chronic (inactive) thyroid eye disease.
Here's Why Momentum Investors Will Love Horizon Therapeutics (HZNP)
01:45pm, Friday, 03'rd Sep 2021
Does Horizon Therapeutics (HZNP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Horizon Therapeutics plc Named One of PEOPLE's 100 Companies That Care®
09:10am, Wednesday, 01'st Sep 2021
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to PEOPLE's 100 Companies That Care® 2021 list for the third year by PEOPLE and Great Place to
CARA Drug Wins FDA Nod for Pruritus Associated With CKD
12:59pm, Tuesday, 24'th Aug 2021
CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
Horizon Therapeutics plc to Participate in Upcoming Conferences
04:01pm, Monday, 23'rd Aug 2021
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conferences: Handelsbanken Life Science Innovation Day 2021 (Virtual
